Charcot-Marie-Tooth DiseaseNCT03715283
Change in MUNIX in Patients With CMT1A Undergoing a Home Ankle Strengthening Program Versus Standard of Care
A study testing Home Ankle Strengthing Program in people with Charcot-Marie-Tooth Disease, run by Vanderbilt University Medical Center at 1 site in United States.
Trial summary
Here the investigators aim to show that a focused lower extremity resistance strength training program in patients with Charcot-Marie-Tooth disease (CMT) results in increased motor strength of ankle plantar- and dorsi-flexion. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Charcot-Marie-Tooth Disease
- What is being tested?
- Home Ankle Strengthing Program
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 19 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Jan 2019to 1 Sep 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Adult Patients 18 years or older with genetically confirmed CMT1A
- Adult Patients 18 years or older with a CMT1A genetically confirmed relative and a positive clinical exam or nerve conduction study consistent with CMT1A.
- Unaffected persons 18 years or older with no past medical history of peripheral neuropathy
Who cannot join
- Patients with a history of medical diseases that affect peripheral nerve function including diabetic neuropathy, uncontrolled thyroid dysfunction, amyloidosis, monoclonal gammopathy of uncertain significance or untreated vitamin deficiencies.
- Patients with a history of other neurologic disease which may affect peripheral nerve function or extremity strength or function including stroke, seizures with a history of Todd's paralysis, Parkinson's Disease, Dementia, Guillen-Barre Syndrome, Myasthenia Gravis, Lambert Eaton Myasthenia Gravis or hypothyroidism.
- Patients with ankle dorsiflexion strength of less than 3/5 in either limb on Medical Research Council scale.
- Patients enrolled in a clinical trial (excluding natural history studies) in the past 12 months.
- Patients who have undergone intense physical therapy, meaning more than 1 time per week for 6 or more weeks within the last 12 months.
- Patient who do resistance training of the lower extremity more than 2 times per week for more than 3 months.
- Patient in whom exercise would be consider dangerous including autonomic failure, postural orthostatic tachycardic syndrome (POTS), lower extremity deep vein thrombosis or pulmonary embolism, arterial insufficiency, uncontrolled pulmonary hypertension, uncontrolled hypertension or uncontrolled heart failure with reduced ejection fraction.
Trial locations and contacts
1 site in 1 country.
United States1 site
Vanderbilt University Medical Center
Nashville, Tennessee, 37212
About this study
Official title: A Randomized Double Blind Longitudinal Study to Determine Motor Unit Number Index Variability in CMT1A Patients Undergoing a Home Ankle Strengthening Program Versus Standard of Care
Here the investigators aim to show that a focused lower extremity resistance strength training program in patients with Charcot-Marie-Tooth disease (CMT) results in increased motor strength of ankle plantar- and dorsi-flexion. The investigators will use motor unit index MUNIX and hand held dynamometry to correlate strength changes. The investigators believe that increased strength will correlate with an increased motor unit number and as such will prove that axonal renervation or improved recruitment is possible with a focused exercises in patients with CMT. Additionally, the investigators will show that that MUNIX declines over a 12-week period in patients with CMT whom continue standard of care. This will identify MUNIX as a responsive marker for disease progression in addition to detecting functional improvement, which will be valuable for future clinical trials.
Read the detailed description
- Overview Previous data in CMT patients on strengthening programs have had mixed results. No studies have demonstrated the effectiveness of a home exercise resistance band training program on ankle dorsiflexion strength in CMT patients. Additionally, it has been shown that that MUNIX is associated with disability scores and could be used as an outcome measure in CMT. Here the investigators will perform a randomized clinical trial to assess the ability of MUNIX to detect longitudinal changes in patients with CMT undergoing an ankle strengthening program.
- AIM 1: To determine if adult patients with CMT1A whom undergo a twelve-week ankle strengthening program will have a significant increase in ankle dorsi- and plantar- flexion, as measured by muscle strength dynamometry compared to patients whom do not undergo the program. Patients enrolled in this study will be randomized to receive either a 12-week home resistance band ankle strengthening program or to continue their current treatment plan. Clinical evaluations and 6-minute walk test will be performed in all enrolled patients, regardless of their arm, at the time of enrollment, 6 and 12 weeks after enrollment. A parallel study of healthy unaffected family members will also be performed in this basis.
- Resistance Band Strengthening Exercises Patients assigned to the strength training group will be a given a twelve-week progressive resistance band program. Study materials in the treatment arm will include a written exercise plan accompanied by a USB and DVD containing demonstration of safe execution of each exercise. Patients in the treatment arm will perform each exercise three times per week. A All exercises are meant to be performed in a seated or lying position for safety.
- Clinical evaluations The investigators will perform all clinical assessments at the Vanderbilt Physical Medicine and Rehabilitation clinic and will be performed by the PI. To maintain blinding by the PI, a pre-determined set of questions will be asked of each patient in order to prevent inadvertent unblinding. Examples of the questionnaires for the 6 and 12 weeks follow up visits are found in the study materials section. . History taking and Neurological examination
- Medical history: The patient will be interviewed by the PI to collect medical history, particularly for symptoms relating the peripheral nerves and family history.
- Neurological examination: Each patient will be examined by the PI. Findings on neurological examination will be recorded, particularly for the sensory and motor functions.
- The Motor portion of the exam will be performed by hand held digital dynamometry as has been previously described
- For the Sensory portion of the exam the investigators will test pinprick, vibratory and light sensations bilaterally
- CMT neuropathy score (CMTNS): This is a simple, extensively validated(16), score system that assesses the disabilities in a patient with CMT. It consists of a brief questionnaire, physical findings and several parameters from nerve conduction studies. For the purposes of this study only the symptom score and examination score. An example of the modified CMTNS is provided in the study materials section.
- 6-minute walk test The six-minute walk test (6MWT) will be performed at the enrollment visit, 6 and 12 weeks after enrollment. This will be performed in the Physical Medicine and Rehabilitation clinic at Vanderbilt University Medical Center. Testing will be conducted as outlined by the American Thoracic Society with some modifications. For the purposes of this study a 10m hallway will be marked with cones. The patient will walk for 6 minutes and forth along the marked hallway. The patient may rest during the 6 minutes. The total distance walked, and number of rest breaks will be recorded. Patients whom use assistive devices such as walkers, canes or ankle braces may will not be asked to undergo the walk if a participant does not feel comfortable ambulating without a device. The PI will accompany each patient with a wheelchair during the entire 6 minutes in case an immediate break is needed. If participants are unable to participate in the 6MWT at the initial visit, participants will be excluded from this portion of the study due to risk of unblinding, but will continue in the study. The 6MWT is contraindicated in patients with unstable angina and those whom have had a myocardial infarction within the last month. Any patient with a positive history will not undergo testing. Each patient will have their seated pulse and blood pressure checked prior to the test. Patients with a pulse rate of 120 beats per minute or greater or a systolic blood pressure greater than 180mmHg (mmHg = millimeter of Mercury) or diastolic blood pressure of 100mmHg or greater will not undergo testing. If elevated blood pressure or pulse is found at the initial clinical encounter, the patient's primary physician will be contacted, and the patient will be brought back at least 2 weeks but no more than 3 weeks later for a blood pressure and pulse check. If the blood pressure or pulse is within the limits defined above, participants will be allowed to undergo testing at this later date. If participants continue to have elevated blood pressure or pulse, participants will not undergo this portion of the study.
- AIM2: MUNIX Studies Procedural and interpretative guidelines for MUNIX have recently been published and will followed in this study. Here the investigators will study the tibialis anterior and abductor hallucis. The tibialis anterior is innervated by deep peroneal branch of the peroneal nerve. Whereas the abductor hallucis is innervated by the tibial nerve. Each muscle will be studied in the extremity with best strength in both ankle dorsiflexion and plantar flexion. If there is a difference between the two muscles the limb with best ankle dorsiflexion strength will be used. All studies will be performed in the VUMC Electrodiagnostic laboratory by the PI.
Prior to the start of the study, lower extremity surface temperature will be measured in the on the lateral aspect of the lower leg that is being tested. If patients surface temperature is below 32oC (or if temperature falls below during the study), a warming pad or heating lamp will be applied. Then at each recording site a supramaximal compound motor unit action potential (CMAP) will be recorded by providing an electrical stimulus over the nerve proximal to the recording sites. There will be at least 3 small adjustments of the recording electrodes to achieve maximal recording of the CMAP. Patients with no response in the CMAP will continue in the study but will be censored from initial analysis such to not askew the data.
Next surface electromyography will be performed by recording the surface interference pattern from the recording site of maximal CMAP. Patients will then perform isometric muscle contractions at 20, 40, 60, 80 and 100% of maximal effort. Following maximal effort patients will be given a 10 second rest period. This will be repeated a total of three times for each nerve tested. The MUNIX will be calculated by a propriety software from Natus (Middleton, WI). As part of the MUNIX output the motor unit size index (MUSIX) will also be obtained.
- Conditions
- Charcot-Marie-Tooth Disease
- Being tested
- Home Ankle Strengthing Program, Standard of Care
- Keywords
- MUNIX
- Medical subject headings
- Charcot-Marie-Tooth Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Home Ankle Strengthing ProgramOther
Patients in this arm will be given a USB or DVD video with description of ankle dorsi- and plantar- flexion resistance band exercise. They will also be given an outlined plan for there exercises, progression and an exercise diary. In general patients will start with a low resistance and low reps, over the 4 weeks they will increase the repetitions at the same resistance band. After the 4 weeks they will have the option to escalate the band resistance or continue at the same resistance and repetitions until comfortable progressing. The same 4 week progression will be used for each resistance band over the 12 weeks.
Standard of CareOther
Patients in this arm will be directed to continue there standard care program. They will be asked to refrain from resistance exercise for 12 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Home Lower Extremity Strengthening | Experimental | Patients in this arm will undergo a 12 week strengthening program which focuses on ankle dorsi- and plantar- flexion. Clinical visits will occur at baseline, 6 weeks and 12 weeks from the start of study. At each visit all patients will undergo a clinical exam, answer questionaires and undergo MUNIX testing. Receives: Other: Home Ankle Strengthing Program |
| No intervention | Experimental | In this portion of the study patients will not be given any intervention. Clinical visits will occur at baseline, 6 weeks and 12 weeks from the start of study. At each visit all patients will undergo a clinical exam, answer questionaires and undergo MUNIX testing of both legs. Receives: Other: Standard of Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in motor unit number index (MUNIX) of the peroneal nerve in the treatment arm versus the untreated arm from baseline to 12 weeks (Peroneal Munix at 12 weeks - Peroneal Munix at baseline,0-1,000a.u., higher numbers represent more motor units)
Measured: 12 weeks
Change in motor unit number index (MUNIX) of the tibial nerve in the treatment arm versus the untreated arm from baseline to 12 weeks (Tibial MUNIX.at 12 weeks - Tibial MUNIX at baseline, 0-1000 arbitrary units, higher numbers represent more motor units)
Measured: 12 weeks
Secondary outcomes (18)
Change in peroneal nerve motor unit number index (MUNIX) at 6 weeks between treatment arms (MUNIX at 6 weeks - MUNIX at Baseline; 0-1000 arbitrary units, higher numbers represent more motor units).
Measured: 6 weeks
Change in tibial nerve compound muscle action potential (CMAP) at 6 weeks between treatment arms ((Tibial CMAP at 6 weeks - Tibial CMAP at baseline (mV) 0-300mV, mV= milliVolts, higher numbers represent more motor units).
Measured: 6 weeks
Change in tibial nerve compound muscle action potential (CMAP) at 12 weeks between treatment arms (Tibial CMAP at 12 weeks - Tibial CMAP at baseline (mV) 0-300mV, mV= milliVolts, higher numbers represent more motor units).
Measured: 12 weeks
Change in peroneal nerve compound muscle action potential (CMAP) at 6 weeks between treatment arms (Peroneal CMAP at 6 weeks - Peroneal CMAP at baseline 0-300mV, mV = milliVolts, higher numbers represent more motor units).
Measured: 6 weeks
Change in peroneal nerve compound muscle action potential (CMAP) at 12 weeks between treatment arms (Peroneal CMAP at 12 weeks - Peroneal CMAP at baseline 0-300mV, mV= milliVolts, higher numbers represent more motor units).
Measured: 12 weeks
Change in muscle strength as measured by dynamometry of ankle dorsiflexion at 6 weeks between treatment arms (dorsiflexion strength at 6 weeks - dorsiflexion strength at baseline 0- 500 N, N=Newton, higher numbers represent means greater strength).
Measured: 6 weeks
Change in muscle strength as measured by dynamometry of ankle dorsiflexion at 12 weeks between treatment arms (dorsiflexion strength at 12 weeks - dorsiflexion strength at baseline 0-500 N, N=Newton, higher numbers represent means greater strength).
Measured: 12weeks
Change in muscle strength as measured by dynamometry of ankle plantarflexion at 6 weeks between treatment arms (plantarflexion strength at 6 weeks - plantarflexion strength at baseline 0-500N, N= Newton, higher numbers represent means greater strength).
Measured: 6 weeks
Change in muscle strength as measured by dynamometry of ankle plantarflexion at 12 weeks between treatment arms (plantarflexion strength at 12 weeks - plantarflexion strength at baseline 0-500N, N= newton higher numbers represent means greater strength).
Measured: 12 weeks
Change in the 6 minute walk test (6MWT) at 6 weeks between treatment arms (6MWT at 6 weeks - 6MWT at baseline 0-5,000m; m = meter, longer distances represent improved functional mobility).
Measured: 6 weeks
Change in the 6 minute walk test (6MWT) at 12 weeks between treatment arms (6MWT at 12 weeks - 6MWT at baseline 0-5,000m; m = meter, longer distances represent improved functional mobility).
Measured: 12 weeks
Change in Charcot Marie Tooth Disease neuropathy score (CMTNS) at 12 weeks between treatment arms (CMTNS at 12 weeks - CMTNS at baseline 0-36 arbitrary units, higher numbers represent more severe disease).
Measured: 12 weeks
Change in Charcot Marie Tooth Disease neuropathy score (CMTNS) at 6 weeks between treatment arms (CMTNS at 6 weeks - CMTNS at baseline 0-36 arbitrary units, higher numbers represent more severe disease).
Measured: 6 weeks
Change in peroneal nerve motor unit size index (MUSIX) at 6 weeks between treatment arms (Peroneal MUSIX at 6 weeks - Peroneal MUSIX at Baseline 0-1,000 arbitrary units, higher number represents more motor units).
Measured: 6 weeks
Change in peroneal nerve motor unit size index (MUSIX) at 12 weeks between treatment arms (Peroneal MUSIX at 12 weeks - Peroneal MUSIX at Baseline 0-1,000 arbitrary units, higher number represents more motor units).
Measured: 12 weeks
Change in tibial nerve motor unit size index (MUSIX) at 6 weeks between treatment arms (Tibial MUSIX at 6 weeks - Tibial MUSIX at Baseline 0-1,000 arbitrary units, higher number represents more motor units).
Measured: 6 weeks
Change in tibial nerve motor unit size index (MUSIX) at 12 weeks between treatment arms (Tibial MUSIX at 12 weeks - Tibial MUSIX at Baseline 0-1,000 arbitrary units, higher number represents more motor units).
Measured: 12 weeks
Change in tibial nerve motor unit number index (MUNIX) at 6 weeks between treatment arms (MUNIX at 6 weeks - MUNIX at Baseline; 0-1000 arbitrary units, higher number represents more motor units).
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Oct 2018
- Study start15 Jan 2019
- Primary completion1 Sep 2019
- Study completion1 Sep 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Charcot-Marie-Tooth DiseaseStudies of the same condition, open and under way.
- More trials run by Vanderbilt University Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 19 participants (actual)
Sponsor and investigators
- Lead sponsor
- Vanderbilt University Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ryan Castoro, Vanderbilt University Medical Center
- Investigators
- Ryan J Castoro, D.O., Principal investigator, Vanderbilt University Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03715283
- Sponsor's protocol ID
- VR52854
- Status last verified
- Dec 2019
- First submitted
- 8 Oct 2018
- Last updated
- 20 Dec 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Li J. Inherited neuropathies. Semin Neurol. 2012 Jul;32(3):204-14. doi: 10.1055/s-0032-1329198. Epub 2012 Nov 1.
PubMed 23117945Nandedkar SD, Barkhaus PE, Stalberg EV. Motor unit number index (MUNIX): principle, method, and findings in healthy subjects and in patients with motor neuron disease. Muscle Nerve. 2010 Nov;42(5):798-807. doi: 10.1002/mus.21824.
PubMed 20976783Bas J, Delmont E, Fatehi F, Salort-Campana E, Verschueren A, Pouget J, Lefebvre MN, Grapperon AM, Attarian S. Motor unit number index correlates with disability in Charcot-Marie-Tooth disease. Clin Neurophysiol. 2018 Jul;129(7):1390-1396. doi: 10.1016/j.clinph.2018.04.359. Epub 2018 Apr 16.
PubMed 29729594
Study at a glance
From the registry record, last updated by the sponsor on 20 Dec 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Double Blind Longitudinal Study to Determine Motor Unit Number Index Variability in CMT1A Patients Undergoing a Home Ankle Strengthening Program Versus Standard of Care
- ClinicalTrials.gov ID
- NCT03715283
- Acronym / sponsor ID
- VR52854
- Conditions
- Charcot-Marie-Tooth Disease
- Keywords
- MUNIX
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 19 participants (actual)
- Lead sponsor
- Vanderbilt University Medical CenterUniversity, hospital or other
- Study start
- 15 Jan 2019 (actual)
- Primary completion
- 1 Sep 2019 (actual)
- Study completion
- 1 Sep 2019 (actual)
- First posted
- 23 Oct 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Here the investigators aim to show that a focused lower extremity resistance strength training program in patients with Charcot-Marie-Tooth disease (CMT) results in increased motor strength of ankle plantar- and dorsi-flexion. The investigators will use motor unit index MUNIX and hand held dynamometry to correlate strength changes. The investigators believe that increased strength will correlate with an increased motor unit number and as such will prove that axonal renervation or improved recruitment is possible with a focused exercises in patients with CMT. Additionally, the investigators will show that that MUNIX declines over a 12-week period in patients with CMT whom continue standard of care. This will identify MUNIX as a responsive marker for disease progression in addition to detecting functional improvement, which will be valuable for future clinical trials.
Detailed description
- Overview Previous data in CMT patients on strengthening programs have had mixed results. No studies have demonstrated the effectiveness of a home exercise resistance band training program on ankle dorsiflexion strength in CMT patients. Additionally, it has been shown that that MUNIX is associated with disability scores and could be used as an outcome measure in CMT. Here the investigators will perform a randomized clinical trial to assess the ability of MUNIX to detect longitudinal changes in patients with CMT undergoing an ankle strengthening program.
- AIM 1: To determine if adult patients with CMT1A whom undergo a twelve-week ankle strengthening program will have a significant increase in ankle dorsi- and plantar- flexion, as measured by muscle strength dynamometry compared to patients whom do not undergo the program. Patients enrolled in this study will be randomized to receive either a 12-week home resistance band ankle strengthening program or to continue their current treatment plan. Clinical evaluations and 6-minute walk test will be performed in all enrolled patients, regardless of their arm, at the time of enrollment, 6 and 12 weeks after enrollment. A parallel study of healthy unaffected family members will also be performed in this basis.
- Resistance Band Strengthening Exercises Patients assigned to the strength training group will be a given a twelve-week progressive resistance band program. Study materials in the treatment arm will include a written exercise plan accompanied by a USB and DVD containing demonstration of safe execution of each exercise. Patients in the treatment arm will perform each exercise three times per week. A All exercises are meant to be performed in a seated or lying position for safety.
- Clinical evaluations The investigators will perform all clinical assessments at the Vanderbilt Physical Medicine and Rehabilitation clinic and will be performed by the PI. To maintain blinding by the PI, a pre-determined set of questions will be asked of each patient in order to prevent inadvertent unblinding. Examples of the questionnaires for the 6 and 12 weeks follow up visits are found in the study materials section. . History taking and Neurological examination
- Medical history: The patient will be interviewed by the PI to collect medical history, particularly for symptoms relating the peripheral nerves and family history.
- Neurological examination: Each patient will be examined by the PI. Findings on neurological examination will be recorded, particularly for the sensory and motor functions.
- The Motor portion of the exam will be performed by hand held digital dynamometry as has been previously described
- For the Sensory portion of the exam the investigators will test pinprick, vibratory and light sensations bilaterally
- CMT neuropathy score (CMTNS): This is a simple, extensively validated(16), score system that assesses the disabilities in a patient with CMT. It consists of a brief questionnaire, physical findings and several parameters from nerve conduction studies. For the purposes of this study only the symptom score and examination score. An example of the modified CMTNS is provided in the study materials section.
- 6-minute walk test The six-minute walk test (6MWT) will be performed at the enrollment visit, 6 and 12 weeks after enrollment. This will be performed in the Physical Medicine and Rehabilitation clinic at Vanderbilt University Medical Center. Testing will be conducted as outlined by the American Thoracic Society with some modifications. For the purposes of this study a 10m hallway will be marked with cones. The patient will walk for 6 minutes and forth along the marked hallway. The patient may rest during the 6 minutes. The total distance walked, and number of rest breaks will be recorded. Patients whom use assistive devices such as walkers, canes or ankle braces may will not be asked to undergo the walk if a participant does not feel comfortable ambulating without a device. The PI will accompany each patient with a wheelchair during the entire 6 minutes in case an immediate break is needed. If participants are unable to participate in the 6MWT at the initial visit, participants will be excluded from this portion of the study due to risk of unblinding, but will continue in the study. The 6MWT is contraindicated in patients with unstable angina and those whom have had a myocardial infarction within the last month. Any patient with a positive history will not undergo testing. Each patient will have their seated pulse and blood pressure checked prior to the test. Patients with a pulse rate of 120 beats per minute or greater or a systolic blood pressure greater than 180mmHg (mmHg = millimeter of Mercury) or diastolic blood pressure of 100mmHg or greater will not undergo testing. If elevated blood pressure or pulse is found at the initial clinical encounter, the patient's primary physician will be contacted, and the patient will be brought back at least 2 weeks but no more than 3 weeks later for a blood pressure and pulse check. If the blood pressure or pulse is within the limits defined above, participants will be allowed to undergo testing at this later date. If participants continue to have elevated blood pressure or pulse, participants will not undergo this portion of the study.
- AIM2: MUNIX Studies Procedural and interpretative guidelines for MUNIX have recently been published and will followed in this study. Here the investigators will study the tibialis anterior and abductor hallucis. The tibialis anterior is innervated by deep peroneal branch of the peroneal nerve. Whereas the abductor hallucis is innervated by the tibial nerve. Each muscle will be studied in the extremity with best strength in both ankle dorsiflexion and plantar flexion. If there is a difference between the two muscles the limb with best ankle dorsiflexion strength will be used. All studies will be performed in the VUMC Electrodiagnostic laboratory by the PI.
Prior to the start of the study, lower extremity surface temperature will be measured in the on the lateral aspect of the lower leg that is being tested. If patients surface temperature is below 32oC (or if temperature falls below during the study), a warming pad or heating lamp will be applied. Then at each recording site a supramaximal compound motor unit action potential (CMAP) will be recorded by providing an electrical stimulus over the nerve proximal to the recording sites. There will be at least 3 small adjustments of the recording electrodes to achieve maximal recording of the CMAP. Patients with no response in the CMAP will continue in the study but will be censored from initial analysis such to not askew the data.
Next surface electromyography will be performed by recording the surface interference pattern from the recording site of maximal CMAP. Patients will then perform isometric muscle contractions at 20, 40, 60, 80 and 100% of maximal effort. Following maximal effort patients will be given a 10 second rest period. This will be repeated a total of three times for each nerve tested. The MUNIX will be calculated by a propriety software from Natus (Middleton, WI). As part of the MUNIX output the motor unit size index (MUSIX) will also be obtained.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Home Lower Extremity Strengthening | Experimental | Other: Home Ankle Strengthing ProgramPatients in this arm will undergo a 12 week strengthening program which focuses on ankle dorsi- and plantar- flexion. Clinical visits will occur at baseline, 6 weeks and 12 weeks from the start of study. At each visit all patients will undergo a clinical exam, answer questionaires and undergo MUNIX testing. |
| No intervention | Experimental | Other: Standard of CareIn this portion of the study patients will not be given any intervention. Clinical visits will occur at baseline, 6 weeks and 12 weeks from the start of study. At each visit all patients will undergo a clinical exam, answer questionaires and undergo MUNIX testing of both legs. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adult Patients 18 years or older with genetically confirmed CMT1A
- Adult Patients 18 years or older with a CMT1A genetically confirmed relative and a positive clinical exam or nerve conduction study consistent with CMT1A.
- Unaffected persons 18 years or older with no past medical history of peripheral neuropathy
Key exclusion criteria (7 listed)
- Patients with a history of medical diseases that affect peripheral nerve function including diabetic neuropathy, uncontrolled thyroid dysfunction, amyloidosis, monoclonal gammopathy of uncertain significance or untreated vitamin deficiencies.
- Patients with a history of other neurologic disease which may affect peripheral nerve function or extremity strength or function including stroke, seizures with a history of Todd's paralysis, Parkinson's Disease, Dementia, Guillen-Barre Syndrome, Myasthenia Gravis, Lambert Eaton Myasthenia Gravis or hypothyroidism.
- Patients with ankle dorsiflexion strength of less than 3/5 in either limb on Medical Research Council scale.
- Patients enrolled in a clinical trial (excluding natural history studies) in the past 12 months.
- Patients who have undergone intense physical therapy, meaning more than 1 time per week for 6 or more weeks within the last 12 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Home Ankle Strengthing ProgramPatients in this arm will be given a USB or DVD video with description of ankle dorsi- and plantar- flexion resistance band exercise. They will also be given an outlined plan for there exercises, progression and an exercise diary. In general patients will start with a low resistance and low reps, over the 4 weeks they will increase the repetitions at the same resistance band. After the 4 weeks they will have the option to escalate the band resistance or continue at the same resistance and repetitions until comfortable progressing. The same 4 week progression will be used for each resistance band over the 12 weeks. | Other | Home Lower Extremity Strengthening |
| Standard of CarePatients in this arm will be directed to continue there standard care program. They will be asked to refrain from resistance exercise for 12 weeks. | Other | No intervention |
Primary outcome
Change in motor unit number index (MUNIX) of the peroneal nerve in the treatment arm versus the untreated arm from baseline to 12 weeks (Peroneal Munix at 12 weeks - Peroneal Munix at baseline,0-1,000a.u., higher numbers represent more motor units)
Time frame: 12 weeks
Change in motor unit number index (MUNIX) of the tibial nerve in the treatment arm versus the untreated arm from baseline to 12 weeks (Tibial MUNIX.at 12 weeks - Tibial MUNIX at baseline, 0-1000 arbitrary units, higher numbers represent more motor units)
Time frame: 12 weeks
18 secondary outcomes
Change in peroneal nerve motor unit number index (MUNIX) at 6 weeks between treatment arms (MUNIX at 6 weeks - MUNIX at Baseline; 0-1000 arbitrary units, higher numbers represent more motor units).
Time frame: 6 weeks
Change in tibial nerve compound muscle action potential (CMAP) at 6 weeks between treatment arms ((Tibial CMAP at 6 weeks - Tibial CMAP at baseline (mV) 0-300mV, mV= milliVolts, higher numbers represent more motor units).
Time frame: 6 weeks
Change in tibial nerve compound muscle action potential (CMAP) at 12 weeks between treatment arms (Tibial CMAP at 12 weeks - Tibial CMAP at baseline (mV) 0-300mV, mV= milliVolts, higher numbers represent more motor units).
Time frame: 12 weeks
Change in peroneal nerve compound muscle action potential (CMAP) at 6 weeks between treatment arms (Peroneal CMAP at 6 weeks - Peroneal CMAP at baseline 0-300mV, mV = milliVolts, higher numbers represent more motor units).
Time frame: 6 weeks
Change in peroneal nerve compound muscle action potential (CMAP) at 12 weeks between treatment arms (Peroneal CMAP at 12 weeks - Peroneal CMAP at baseline 0-300mV, mV= milliVolts, higher numbers represent more motor units).
Time frame: 12 weeks
Change in muscle strength as measured by dynamometry of ankle dorsiflexion at 6 weeks between treatment arms (dorsiflexion strength at 6 weeks - dorsiflexion strength at baseline 0- 500 N, N=Newton, higher numbers represent means greater strength).
Time frame: 6 weeks
Change in muscle strength as measured by dynamometry of ankle dorsiflexion at 12 weeks between treatment arms (dorsiflexion strength at 12 weeks - dorsiflexion strength at baseline 0-500 N, N=Newton, higher numbers represent means greater strength).
Time frame: 12weeks
Change in muscle strength as measured by dynamometry of ankle plantarflexion at 6 weeks between treatment arms (plantarflexion strength at 6 weeks - plantarflexion strength at baseline 0-500N, N= Newton, higher numbers represent means greater strength).
Time frame: 6 weeks
Change in muscle strength as measured by dynamometry of ankle plantarflexion at 12 weeks between treatment arms (plantarflexion strength at 12 weeks - plantarflexion strength at baseline 0-500N, N= newton higher numbers represent means greater strength).
Time frame: 12 weeks
Change in the 6 minute walk test (6MWT) at 6 weeks between treatment arms (6MWT at 6 weeks - 6MWT at baseline 0-5,000m; m = meter, longer distances represent improved functional mobility).
Time frame: 6 weeks
Change in the 6 minute walk test (6MWT) at 12 weeks between treatment arms (6MWT at 12 weeks - 6MWT at baseline 0-5,000m; m = meter, longer distances represent improved functional mobility).
Time frame: 12 weeks
Change in Charcot Marie Tooth Disease neuropathy score (CMTNS) at 12 weeks between treatment arms (CMTNS at 12 weeks - CMTNS at baseline 0-36 arbitrary units, higher numbers represent more severe disease).
Time frame: 12 weeks
Change in Charcot Marie Tooth Disease neuropathy score (CMTNS) at 6 weeks between treatment arms (CMTNS at 6 weeks - CMTNS at baseline 0-36 arbitrary units, higher numbers represent more severe disease).
Time frame: 6 weeks
Change in peroneal nerve motor unit size index (MUSIX) at 6 weeks between treatment arms (Peroneal MUSIX at 6 weeks - Peroneal MUSIX at Baseline 0-1,000 arbitrary units, higher number represents more motor units).
Time frame: 6 weeks
Change in peroneal nerve motor unit size index (MUSIX) at 12 weeks between treatment arms (Peroneal MUSIX at 12 weeks - Peroneal MUSIX at Baseline 0-1,000 arbitrary units, higher number represents more motor units).
Time frame: 12 weeks
Change in tibial nerve motor unit size index (MUSIX) at 6 weeks between treatment arms (Tibial MUSIX at 6 weeks - Tibial MUSIX at Baseline 0-1,000 arbitrary units, higher number represents more motor units).
Time frame: 6 weeks
Change in tibial nerve motor unit size index (MUSIX) at 12 weeks between treatment arms (Tibial MUSIX at 12 weeks - Tibial MUSIX at Baseline 0-1,000 arbitrary units, higher number represents more motor units).
Time frame: 12 weeks
Change in tibial nerve motor unit number index (MUNIX) at 6 weeks between treatment arms (MUNIX at 6 weeks - MUNIX at Baseline; 0-1000 arbitrary units, higher number represents more motor units).
Time frame: 6 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Dec 2019.
- Background: PubMed 23117945Li J. Inherited neuropathies. Semin Neurol. 2012 Jul;32(3):204-14. doi: 10.1055/s-0032-1329198. Epub 2012 Nov 1.
- Background: PubMed 20976783Nandedkar SD, Barkhaus PE, Stalberg EV. Motor unit number index (MUNIX): principle, method, and findings in healthy subjects and in patients with motor neuron disease. Muscle Nerve. 2010 Nov;42(5):798-807. doi: 10.1002/mus.21824.
- Background: PubMed 29729594Bas J, Delmont E, Fatehi F, Salort-Campana E, Verschueren A, Pouget J, Lefebvre MN, Grapperon AM, Attarian S. Motor unit number index correlates with disability in Charcot-Marie-Tooth disease. Clin Neurophysiol. 2018 Jul;129(7):1390-1396. doi: 10.1016/j.clinph.2018.04.359. Epub 2018 Apr 16.
- Individual participant dataSharing planned: No
Related trials for Charcot-Marie-Tooth Disease
Active, not recruiting
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis
RecruitingPhase 2
Study on Thiamine Supplementation to REduce braiN Injury Associated With Chronic Alcohol Use in Outpatients With Alcohol Use Disorder
Alcohol Use Disorder
RecruitingObservational study
Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP
Charcot-Marie-Tooth, CMT1A
Recruiting
High-Tech Rehabilitation Pathway for Chronic Adult Neuromuscular Diseases - Fit4MedRob-Chronic MND Project
Amyotrophic Lateral Sclerosis, Chronic Inflammatory Demyelinating Neuropathy
Recruiting
Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic Volunteers
Spinal Muscular Atrophy (SMA), Charcot-Marie-Tooth
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ryan J Castoro, D.O. principal investigator
Vanderbilt University Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Home Ankle Strengthing Program in people with Charcot-Marie-Tooth Disease, run by Vanderbilt University Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Dec 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in motor unit number index (MUNIX) of the peroneal nerve in the treatment arm versus the untreated arm from baseline to 12 weeks (Peroneal Munix at 12 weeks - Peroneal Munix at baseline,0-1,000a.u., higher numbers represent more motor units) (time frame: 12 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03715283, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2019; AzTrials last refreshed its copy on 7 Nov 2026.